Table 1.
Statistical analysis of the effects of thioperamide treatment and vestibular lesions (unilateral, bilateral one or two steps) on the histaminergic system at the molecular level
| Source of variation | d.f. | F | P |
|---|---|---|---|
| HDC mRNA | |||
| Controls/UVN cats | 3 | 14.22 | 0.0001* |
| Controls/one-step bilateral cats | 1 | 0.006 | 0.94 |
| Controls/two-step bilateral cats | 1 | 26.28 | 0.0001* |
| Treatment (T/NT) | 1 | 9.07 | 0.003* |
| Survival period (1w, 3 w versus 3 months) | 2 | 11.91 | 0.0001* |
| Silver grain number per HDC neurons | |||
| Controls/UVN cats | 3 | 47.22 | 0.0001* |
| Controls/one-step bilateral cats | 1 | 2.75 | 0.1 |
| Controls/two-step bilateral cats | 1 | 65.82 | 0.0001* |
| Treatment (T/NT) | 1 | 86.89 | 0.0001* |
| Survival period (1w, 3 w versus 3 months) | 2 | 40.09 | 0.0001* |
| Number of HDC-radiolabelled neurons | |||
| Controls/UVN cats | 3 | 1.45 | 0.22 |
| Controls/one-step bilateral cats | 1 | 0.023 | 0.87 |
| Controls/two-step bilateral cats | 1 | 0.52 | 0.46 |
| Treatment (T/NT) | 1 | 0.27 | 0.59 |
| Survival period (1w, 3 w versus 3 months) | 2 | 1.44 | 0.23 |
| H3 receptor-binding sites | |||
| Controls/UVN cats (lesioned side) | 1 | 14.35 | 0.0002* |
| Controls/treated cats (both sides) | 1 | 548.13 | 0.0001* |
| UVN cats/thioperamide-treated cat | 1 | 450.45 | 0.0001* |
| UVN cats (intact side lesioned−1 side) | 1 | 47.87 | 0.0001* |
Repeated-measures analysis of variance of the HDC mRNA labelled surface (in square pixels), the number of silver grains per histidine decarboxylase radiolabelled neurons, the number of histidine decarboxylase radiolabelled neurons in the tuberomammillary nuclei, and the number of histamine H3 receptor binding sites (fmol (mg protein)−1) in the medial vestibular nuclei (VMN). Group, vestibular lesion, treatment, and survival period are the main fixed effects providing the sources of variation among cats
*
d.f.: degree of freedom; F: Scheffé's test; P: probability level.